Keyphrases
Acute Myeloid Leukemia
100%
Venetoclax
70%
Newly Diagnosed
27%
Overall Survival
24%
Intensive Chemotherapy
24%
Decitabine
23%
Hypomethylating Agents
22%
Relapsed or Refractory Acute Myeloid Leukemia
21%
Complete Remission
20%
Chronic Myeloid Leukemia
15%
Myelodysplastic Syndrome
14%
Relapsed or Refractory
13%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
13%
Phase II Trial
13%
Phase II Study
12%
Event-free Survival
10%
High Risk
10%
Minimal Residual Disease
9%
Blast Phase
8%
Median Overall Survival
8%
Induction Chemotherapy
8%
Azacitidine
8%
Overall Response Rate
7%
Improved Outcomes
7%
Unfit Patients
7%
Isocitrate Dehydrogenase 1 (IDH1)
7%
Older Patients
7%
B-cell Lymphoma 2 (Bcl-2)
7%
Leukemia
7%
Confidence Interval
6%
Treatment Strategy
6%
Propensity Score Analysis
6%
Secondary Acute Myeloid Leukemia (sAML)
6%
Frontline Treatment
6%
FLT3 mutation
6%
FLT3 Inhibitor
6%
Tumor Protein p53 (TP53)
5%
Older Adults
5%
FLAG-Ida
5%
Myeloid Blasts
5%
Enasidenib
5%
Cedazuridine
5%
Gemtuzumab Ozogamicin
5%
RAS mutant
5%
Hazard Ratio
5%
MD Anderson Cancer Center
5%
Refractory AML
5%
Treatment Regimen
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
82%
Venetoclax
59%
Chemotherapy
30%
Overall Survival
23%
Decitabine
18%
Remission
17%
Myelodysplastic Syndrome
13%
Leukemia
10%
Protein Tyrosine Kinase Inhibitor
9%
Chronic Myeloid Leukemia
9%
Minimal Residual Disease
8%
Malignant Neoplasm
8%
Azacitidine
8%
Diseases
7%
Myeloid Leukemia
7%
Secondary Acute Myeloid Leukemia
6%
Philadelphia 1 Chromosome
5%
Enasidenib
5%
Acute Lymphoblastic Leukemia
5%
Adverse Event
5%
Event Free Survival
5%
Clinical Trial
5%
Medicine and Dentistry
Acute Myeloid Leukemia
83%
Venetoclax
62%
Overall Survival
30%
Decitabine
24%
Hypomethylating Agent
18%
Tyrosine-Kinase Inhibitor
9%
Leukemia
9%
Minimal Residual Disease
8%
Induction Chemotherapy
8%
Myelodysplastic Syndrome
8%
Event Free Survival
8%
Cancer
7%
Myeloid Leukemia
7%
Malignant Neoplasm
6%
Allogeneic Stem Cell Transplantation
6%
Chronic Myelogenous Leukemia
6%
Meta-Analysis
5%
Cedazuridine
5%
Pediatrics
5%
Secondary Acute Myeloid Leukemia
5%
Hazard Ratio
5%
Infection
5%
Neoplasm
5%
Recurrence Free Survival
5%